US digital health platform company imaware has acquired binx health’s at-home consumer testing business. The acquisition will expand imaware’s position in the growing US market for home-health testing and expand the company’s number of enterprise clients.
Since its creation in 2017, binx health’s consumer division has delivered millions of tests, serviced hundreds of business partners, and generated tens of millions of dollars in revenue. imaware, founded in 2018, offers a broad array of home testing options for employers, health systems, and directly to consumers. binx health will retain and continue to grow its point-of-care molecular diagnostics business, which is excluded from the imaware transaction.
“It’s gratifying to see so many people who now have expanded access to testing from home through unique digital health offerings and advanced logistics,” said Jeff Luber, binx health CEO and founder of the binx health consumer division. “binx will retain and continue to grow its point-of-care molecular division and spin out our digital health at-home business to imaware and its institutional backers. imaware is an ideal choice for us as it has quietly built a stunning franchise in consumer health.”
“We built imaware to be the leading brand of at-home testing with a focus on scientific pedigree, and our clients and patients expect our tests to deliver results equivalent to existing gold standard methods” said Jani Tuomi, Co-founder of imaware. “We are excited to work with the binx team to acquire their top-quality consumer testing business, grow this business, and expand the depth of tests we offer their clients. The binx business fits perfectly into our high growth plans for the coming years.”
binx health is a healthcare technology and diagnostics company focused on innovating solutions to improve routine testing. The binx io point-of-care molecular platform (pictured above) is the first ever FDA-cleared, CLIA-waived point-of-care system for the detection of chlamydia and gonorrhea in both males (urine) and females (vaginal swab) that provides laboratory standard results in about thirty minutes.
The imaware patient-facing platform offers scientifically validated home-based tests that screen and monitor a wide range of conditions across men's health, women's health, COVID-19, allergic diseases, autoimmune diseases, preventative genetics, and more. The firm’s technology solutions provide patients, providers, employers, and brands with access to a digitally-native care model that includes logistics, CLIA/CAP-certified laboratory analysis, telehealth support, and compliance expertise.